Почетна › Рак на бели дробови со не-мали клетки › Мичиген › Ann Arbor
Клинички испитувања за Рак на бели дробови со не-мали клетки во Ann Arbor, MI
26 студии за Рак на бели дробови со не-мали клетки бараат учесници на локации во и околу Ann Arbor (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Се регрутираФаза 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · на 7 милји
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 милји
- и уште 4
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Се регрутираФаза 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 милји
- Chelsea Hospital, Chelsea · на 15 милји
- и уште 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Се регрутираФаза 3
- University of Michigan Rogel Cancer Center, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 милји
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · на 15 милји
- и уште 2
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Се регрутираФаза 3
- Trinity Health Ann Arbor Hospital, Ann Arbor
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- University of Michigan Health System, Ann Arbor
- Trinity Health St Joseph Mercy Ann Arbor, Ypsilanti · на 7 милји
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Се регрутираФаза 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · на 7 милји
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 милји
- и уште 4
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Се регрутираФаза 1
- University of Michigan Health Systems, Ann Arbor
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Се регрутираФаза 1/2
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Се регрутираФаза 3
- Clinical Study Site, Ann Arbor
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- University of Michigan, Ann Arbor
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Се регрутираФаза 1
- University of Michigan, Ann Arbor
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Се регрутираФаза 3
- University of Michigan, Ann Arbor
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Се регрутираФаза 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9552), Ypsilanti · на 7 милји
Gilteritinib for the Treatment of ALK NSCLC
Се регрутираФаза 1
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Се регрутираФаза 1
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 252010, Ann Arbor
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Се регрутираФаза 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · на 7 милји
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 милји
- и уште 4
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 милји
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · на 15 милји
- и уште 1
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2/3
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 милји
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · на 15 милји
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · на 18 милји
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · на 7 милји
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 милји
- и уште 4
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Се регрутираФаза 1/2
- University of Michigan, Ann Arbor
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Се регрутираНабљудувачка студија
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Repositioning Immunotherapy in VetArans With Lung Cancer
Се регрутираФаза 2
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Се регрутираФаза 2
- University of Michigan (Data Collection Only), Ann Arbor
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Се регрутира
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Се регрутираФаза 1/2
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Се регрутираНабљудувачка студија
- Massive Bio SYNERGY-AI site, Ann Arbor
Испитувања за Рак на бели дробови со не-мали клетки во други градови
- Houston, TX145 студии
- New York City, NY121 студија
- Arlington, VA104 студии
- Nashville, TN97 студии
- Boston, MA90 студии
- Los Angeles, CA87 студии
- St. Louis, MO73 студии
- Chicago, IL61 студија
- Baltimore, MD60 студии
- San Antonio, TX59 студии
- Columbus, OH57 студии
- Washington, DC55 студии
Други студии во Ann Arbor
- Рак на дојка27 студии
- Рак на простата27 студии
- Рак (сите типови)25 студии
- Рак на бели дробови23 студии
- Колоректален карцином23 студии
- Срцева слабост22 студии
- Акутна миелоидна леукемија17 студии
- Кардиоваскуларни болести16 студии
- Карцином на панкреасот14 студии
- Меланом12 студии
- Шлог12 студии
- Сквамозноклеточен карцином на глава и врат12 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.